These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 4113156)

  • 1. Comparison of an immunoresistant and an immunosusceptible ascites subline from murine tumor TA3. II. Immunosensitivity and antibody-binding capacity in vitro, and immunogenicity in allogeneic mice.
    Friberg S
    J Natl Cancer Inst; 1972 May; 48(5):1477-89. PubMed ID: 4113156
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of an immunoresistant and an immunosusceptible ascites subline from murine tumor TA3. I. Transplantability, morphology, and some physicochemical characteristics.
    Friberg S
    J Natl Cancer Inst; 1972 May; 48(5):1463-76. PubMed ID: 5030958
    [No Abstract]   [Full Text] [Related]  

  • 3. Transplantability and antigenicity of two sublines of the TA3 tumor.
    Sanford BH; Codington JF; Jeanloz RW; Palmer PD
    J Immunol; 1973 May; 110(5):1233-7. PubMed ID: 4572632
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
    Rapp L; Fuji H
    Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allograft immunity in the mouse. 1. Quantitation and specificity of cytotoxic effector cells after in vitro sensitization.
    MacDonald HR; Phillips RA; Miller RG
    J Immunol; 1973 Aug; 111(2):565-74. PubMed ID: 4123983
    [No Abstract]   [Full Text] [Related]  

  • 6. H-2 immunogenicity of various tissue extracts as detected by growth of an allogeneic tumour.
    Hilgert I; Koubek K; Kristofová H
    Folia Biol (Praha); 1971; 17(2):73-85. PubMed ID: 4102583
    [No Abstract]   [Full Text] [Related]  

  • 7. In vivo activity of in vitro immunized lymphocytes. I. Tumor allograft rejection mediated by in vitro activated mouse thymocytes.
    Rouse BT; Wagner H; Harris AW
    J Immunol; 1972 May; 108(5):1353-61. PubMed ID: 4623947
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune response to a mammary adenocarcinoma. IV. Blocking of cell-mediated cytolysis by immunoglobulins binding to immune lymphocytes.
    Huber SA; Lucas ZJ
    J Immunol; 1977 Aug; 119(2):726-36. PubMed ID: 328781
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunity to a TA3 tumor subline that grows in allogeneic hosts elicited by strain-specific TA3 tumor cells.
    Lippman MM; Venditti JM; Kline I; Elam DL
    Cancer Res; 1973 Apr; 33(4):679-84. PubMed ID: 4696468
    [No Abstract]   [Full Text] [Related]  

  • 10. Sensitivity of tumour and normal cells to the effect of immune lymphocytes in vitro and some properties of target cells determing this sensitivity.
    Lavrovsky VA; Razvorotnev VA
    Folia Biol (Praha); 1976; 22(2):108-15. PubMed ID: 776718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of strain specificity of the TA3-St subline: evidence for the role of epiglycanin in mouse allogeneic tumor growth.
    Cooper AG; Codington JF; Miller DK; Brown MC
    J Natl Cancer Inst; 1979 Jul; 63(1):163-9. PubMed ID: 221714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cellular mechanisms of transplantation and tumor immunity].
    Brunner KT
    Schweiz Med Wochenschr; 1972 Aug; 102(33):1144-7. PubMed ID: 4403396
    [No Abstract]   [Full Text] [Related]  

  • 13. Intercellular communication in cell-mediated cytotoxicity. Fluorescein transfer between H-2 d target cells and H-2 b lymphocytes in vitro.
    Sellin D; Wallach DF; Fischer H
    Eur J Immunol; 1971 Dec; 1(6):453-8. PubMed ID: 4112276
    [No Abstract]   [Full Text] [Related]  

  • 14. Physicochemical and morphological characterization of a new allotransplantable mammary carcinoma ascites subline, TA3-St/ticol/-A.
    Codington JF; Dalianis T; Miller SC; Das HR; Klein G; Lampert LA; Silber C; Darby DM; Jeanloz RW
    Cancer Res; 1983 Sep; 43(9):4364-72. PubMed ID: 6871869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing antibody: in vitro studies on mechanism of action upon the sensitization and effector arc.
    Phillips SM; Strom TB; Corson JM; Carpenter CB; Merrill JP
    Transplant Proc; 1973 Mar; 5(1):577-80. PubMed ID: 4266670
    [No Abstract]   [Full Text] [Related]  

  • 16. The immunologic response to xenografts. Recognition of mouse H-2 histocompatibility antigens by the rat.
    Sachs DH; Winn HJ; Russell PS
    J Immunol; 1971 Aug; 107(2):481-92. PubMed ID: 4936290
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of macrophages in tumour immunity. II. Involvement of a macrophage cytophilic factor during syngeneic tumour growth inhibition.
    Evans R; Alexander P
    Immunology; 1972 Oct; 23(4):627-36. PubMed ID: 4563478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The application of an in vitro cytotoxicity test to studies of the effects of drugs on the cellular immune response in mice. I. Primary response.
    Fass L; Fefer A
    J Immunol; 1972 Oct; 109(4):749-53. PubMed ID: 5074330
    [No Abstract]   [Full Text] [Related]  

  • 19. Studies on the FMR antigen.
    Lilly F; Nathenson SG
    Transplant Proc; 1969 Mar; 1(1):85-9. PubMed ID: 4332534
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunogenicity of spermatozoa.
    Brannen GE; Klein DL
    Invest Urol; 1974 Nov; 12(3):193-9. PubMed ID: 4140848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.